



## Artery Research

ISSN (Online): 1876-4401

ISSN (Print): 1872-9312

Journal Home Page: <https://www.atlantis-press.com/journals/artres>

---

### **P2.07: DOES ROSUVASTATIN MEDIATES A BETTER CONTROL OF CENTRAL BLOOD PRESSURE IN TREATED HYPERTENSIVES PATIENTS?**

J. Chiabaut Svane, P. Forcada, S. Gonzalez, S. Obregon, C. Castellaro Bello, F. Inserra, E. Cavanagh, C. Kotliar

**To cite this article:** J. Chiabaut Svane, P. Forcada, S. Gonzalez, S. Obregon, C. Castellaro Bello, F. Inserra, E. Cavanagh, C. Kotliar (2010) P2.07: DOES ROSUVASTATIN MEDIATES A BETTER CONTROL OF CENTRAL BLOOD PRESSURE IN TREATED HYPERTENSIVES PATIENTS?, Artery Research 4:4, 158–158, DOI: <https://doi.org/10.1016/j.artres.2010.10.040>

**To link to this article:** <https://doi.org/10.1016/j.artres.2010.10.040>

Published online: 21 December 2019

arterial wall function in patients with documented coronary heart disease and dyslipidemia in 24 weeks' randomized controlled trial.

**Methods:** 60 patients (32 men, 28 women, age  $61 \pm 8$ ) were randomized into 4 groups with equal number of pts ( $n = 15$ ). In each group pts received drugs as monotherapy: EZ 10mg, simvastatin 10mg, atorvastatin 10mg, rosuvastatin 10mg. After 12 weeks, if LDL-cholesterol (LDL-C) level was more than  $2,5 \text{ mmol/l}$  in statins monotherapy treatment, EZ 10 mg was added. LDL-C, stiffness parameter  $\beta$ , compliance (CC) and distensibility (DC) coefficients were determined by high-resolution ultrasound before and after 12 and 24 weeks of treatment. For analysis pts were reform in 3 groups: 1 - pts taken only EZ ( $n = 15$ ), 2 - pts taken only statins ( $n = 19$ ), 3 - pts taken combination statins and EZ ( $n = 24$ ).

**Results:** After 12 and 24 weeks of treatment the level of LDL-C significantly decreased in all groups. Stiffness, CC and DC also was significantly changed (in table below, % changes from baseline).

**Conclusions:** Arterial stiffness, compliance and distensibility are significantly changed after 12 and 24 weeks of treatment in all groups. We did not find significantly intergroup differences of these parameters.

weeks	EZ		Statins		Statins and EZ	
	12	24	12	24	12	24
LDL-C, %	- 16,4 <sup>^</sup>	- 11,2 <sup>°</sup>	- 34,7*	- 43*	- 25 <sup>°</sup>	- 45,7 <sup>^</sup>
$\beta$ , %	- 20*	- 32,5*	- 22,6*	- 29*	- 11,4*	- 20*
CC, %	+10 n/s	+ 26 <sup>°</sup>	+5,5 n/s	+ 18 <sup>°</sup>	+ 5,6 n/s	+ 25 <sup>°</sup>
DC, %	+ 21*	+ 41*	+ 13 <sup>^</sup>	+ 27*	+ 11 <sup>°</sup>	+ 20 <sup>°</sup>

\* -  $p < 0,001$ , <sup>^</sup> -  $p < 0,01$ , <sup>°</sup> -  $p < 0,05$ , n/s - no significantly.

#### P2.06

##### EFFECT OF PARICALCITOL AND ALFACALCIDOL ON ARTERIAL STIFFNESS IN CHRONIC HEMODIALYSIS PATIENTS

D. Hansen <sup>1</sup>, S. Thinesh Kumar <sup>2</sup>, L. Brandt <sup>1</sup>, K. Rasmussen <sup>1</sup>

<sup>1</sup>Roskilde Hospital, Roskilde, Denmark

<sup>2</sup>Odense University Hospital, Odense, Denmark

**Background:** The incidence of cardiovascular disease in hemodialysis (HD) patients is high. Disorders of the mineral metabolism seem to play a critical role. Epidemiological studies have found an increased survival in HD patients receiving vitamin D receptor analogs (VDRA) and a difference in survival depending on kind of VDRA used. Augmentation index (Aix) and pulse wave velocity (PWV) are strong predictors of cardiovascular mortality in hemodialysis patients. Whether treatment with VDRA influence on Aix and PWV in hemodialysis patients are unknown.

**Methods:** Eight subjects (6 male) mean(SD) age  $74.3(10.4)$  with secondary hyperparathyroidism receiving chronic hemodialysis therapy were randomized to 16 weeks of treatment with paricalcitol or alfacalcidol (6/2). A wash out period of six weeks preceded the treatment. Aortic stiffness was evaluated with aorticPWV and wave reflections with Aix by applanation tonometry (Sphygmocor) at the beginning and at the end of the treatment period.

**Results:** Overall treatment with VDRA seemed to decrease heart rate adjusted Aix ( $-14.2 \pm 7.7\%$ , n.s.), PWV were unchanged ( $0.8 \pm 5.1\%$ ).

There was a significant difference in the effect of the two VDRA on PWV. Paricalcitol decreased PWV while alfacalcidol increased PWV ( $-4.9 \pm 4.7$  vs.  $17.6 \pm 2.0\%$ ;  $p < 0.05$ ). There were not any difference in changes in Aix between paricalcitol treated patients or alfacalcidol treated patients ( $-13.1 \pm 6.4$  vs.  $-17.6 \pm 17.4\%$ ; n.s)

**Conclusion:** VDRA tends to decrease Aix. Paricalcitol improve whereas alfacalcidol worsens PWV. These findings are coherent with present epidemiologic studies. Larger studies are needed to confirm these results.

#### P2.07

##### DOES ROSUVASTATIN MEDIATES A BETTER CONTROL OF CENTRAL BLOOD PRESSURE IN TREATED HYPERTENSIVES PATIENTS?

J. Chiabaut Svane, P. Forcada, S. Gonzalez, S. Obregon, C. Castellaro Bello, F. Inserra, E. Cavanagh, C. Kotliar  
Hospital Universitario Austral, Pilar, Argentina

**Introduction:** The pleiotropic antiatherosclerotic effects of statins have been widely described and were proposed to mediate a potential antihypertensive action. However, statin indication in hypertensives with subclinical atherosclerosis is still controversial.

Based on these observations, we decided to evaluate the effect of rosuvastatin on central arterial pressure and arterial stiffness by using noninvasive tests.

**Aim:** To evaluate rosuvastatin effects on: a) central and peripheral blood pressure, aortic and peripheral augmentation index and b) arterial stiffness.

**Material and methods:** We included 79 consecutive essential hypertensives under stable antihypertensive drug treatment. All patients were subjected to a 3-month intensive diet and physical activity period; and were allocated to: a) rosuvastatin (20 mg/day, OD) or b) no rosuvastatin treatment. The following determinations were conducted at the beginning and after a 1 year follow-up period: Total/HDL/LDL cholesterol; triglycerides; pulse wave velocity (Complior<sup>®</sup>), central blood pressure and Augmentation Index (Tensioclinic<sup>®</sup>).

**Results:** No differences in basal population characteristics were found between the two groups. At follow-up the rosuvastatin group showed a significant reduction in all the parameters studied (table 1 and figure 1).

**Conclusion:** These findings suggest that in stabilized hypertensives subjects, rosuvastatin is associated with an antihypertensive effect on top of the specific antihypertensive treatment. This effect is predominant for central blood pressure variables and is accompanied with a significant improvement in arterial stiffness.

Statin effects on peripheral artery distensibility may mediate a secondary relief of aortic load conditions. Further studies are needed to evaluate the potential implication of these findings for hypertensive patients.

#### P2.08

##### ARE CENTRAL PULSE WAVE INDICES SUPERIOR OVER BRACHIAL BLOOD PRESSURE IN PREDICTION OF LEFT VENTRICULAR MASS IN YOUNG MEN?

Y. Kotovskaya, R. Kobzev, A. Safarova, R. Akhmetov, Z. Kobalava  
Russian People's Friendship University, Moscow, Russian Federation

**Objective:** Central BP (cBP) stronger correlates with target organ damage than casual brachial BP. pportive data for superiority of cBP over ambulatory BP. The aim of the study was to evaluate correlation between left ventricular mass index (LVMI) and central, clinic and ambulatory BP in young men.

**Methods:** 196 male subjects 18-25 ( $21 \pm 1,4$ ) years with a history of casual BP elevation underwent routine physical, laboratory and instrumental tests, ABPM and pulse wave analysis (Sphygmocor, AtCor, Australia). Arterial hypertension (AH) was considered sustained if both clinic BP and ABPM values exceeded recommended diagnostic thresholds. Observed/predicted LVM ratio (OPLVMR) was assessed using de Simone et al. approach. Spearman analysis was performed to assess correlation between LVMI and OPLVMR.

**Results:** 24-h and daytime SBP ( $r = 0,30$  and  $r = 0,31$ ,  $p < 0,001$ ) slightly stronger than clinic SBP ( $r = 0,27$ ,  $p < 0,001$ ) correlated with LVMI. Correlation between cPP and LVMI was  $r = 0,26$ ,  $p = < 0,001$ . No significant correlation was found between clinic BP and OPLVMR. Stronger correlation with OPLVMR was observed for 24-h and daytime SBP ( $r = 0,32$ ,  $p = 0,001$ ) than for cPP ( $r = 0,25$ ,  $p = 0,01$ ). In patients with sustained AH ( $n = 114$ ) no significant correlation between clinic BP, ABPM or cPP and LVMI or OPLVMR was found but negative significant correlation was observed between PP amplification and LVMI ( $r = - 0,20$ ,  $p = 0,03$ ) and positive with PP Aix  $r = 0,21$ ,  $p = 0,02$ ).

**Conclusion:** cBP seems not to be superior ABPM for LVMI and OPLVMR prediction. Correlations between PP amplification and Aix and LVMI in subjects with sustained AH may confirm impact of early changes of arterial stiffness for target organ damage in young hypertensive population.

#### P2.09

##### MATERNAL CENTRAL BLOOD PRESSURE, WAVE REFLECTION AND ARTERIAL STIFFNESS IN COMPLICATED PREGNANCY

Y. Kotovskaya, V. Kicheeva, Z. Kobalava  
Russian People's Friendship University, Moscow, Russian Federation

**Objective:** Pregnancy is associated with profound alterations in the maternal cardiovascular system. The aim of the study was to assess using applanation tonometry (AT) the maternal central aortic blood pressures (BP), wave reflection and arterial stiffness in pregnancy complicated with threatened abortion.

**Methods:** Radial AT (Sphygmocor; AtCor Medical) was performed in 55 women (mean age  $26,8 \pm 5,6$  years) with singleton pregnancies at 5 to 22 weeks of gestation. All women had pregnancies complicated by threatened abortion. Central BP and augmentation index (Aix) - a measure of arterial wave reflection - were assessed using pulse wave analysis of the radial artery waveform and a validated transfer function. Pulse wave velocity (PWV) measurement on carotid-femoral segment was performed to evaluate arterial stiffness. Brachial BP measured with mercury sphygmomanometer by